Skip to main content
Erschienen in: Clinical and Translational Oncology 8/2018

11.01.2018 | Research Article

A SUVmax-based propensity matched analysis of stereotactic body radiotherapy versus surgery in stage I non-small cell lung cancer: unveiling the role of 18F-FDG PET/CT in clinical decision-making

Erschienen in: Clinical and Translational Oncology | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

The value of maximum standard uptake value (SUVmax) was overlooked in current studies comparing stereotactic body radiotherapy (SBRT) versus surgery for stage I non-small cell lung cancer (NSCLC). Herein, we aimed to compare the 3-year outcomes based on patients for whom SUVmax were available, and to explore the role of SUVmax in clinical decision-making.

Methods

From January 2010 to June 2016, data of eligible patients were collected. Patient variables and clinical outcomes were compared in both unmatched and matched groups using propensity score matching (PSM). Multivariate analysis was performed for predictors of poor outcome. The relationship between treatment approach and survival outcome was also evaluated in subgroup patients stratified by SUVmax level.

Results

A total of 425 patients treated with either surgery (325) or SBRT (100) were included. Patients receiving SBRT were significantly older, had a higher level of SUVmax and were more likely to have tumor of centrally located. Multivariate analysis showed that SUVmax and tumor size were significant predictors for 3-year OS, LRC, and PFS, while better PFS was also related to peripheral tumor and surgery. The result of PSM analysis also showed that compared to SBRT, surgery could only achieve better PFS. Subgroup analysis indicated that surgery had added advantage of 3-year LRC and PFS for patients in high SUVmax group (SUVmax > 8), but not in low SUVmax group.

Conclusions

The study found a superior PFS after surgery while OS and LRC did not differ between SBRT and surgery. Surgery should be recommended for tumor of high SUVmax.
Literatur
2.
Zurück zum Zitat Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011;81:1352–8.CrossRefPubMed Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011;81:1352–8.CrossRefPubMed
3.
Zurück zum Zitat Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16:630–7.CrossRefPubMedPubMedCentral Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16:630–7.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Falkson CB, Vella ET, Yu E, El-Mallah M, Mackenzie R, Ellis PM, et al. Radiotherapy with curative intent in patients with early-stage, medically inoperable, non-small-cell lung cancer: a systematic review. Clini Lung Cancer. 2017;18:105.CrossRef Falkson CB, Vella ET, Yu E, El-Mallah M, Mackenzie R, Ellis PM, et al. Radiotherapy with curative intent in patients with early-stage, medically inoperable, non-small-cell lung cancer: a systematic review. Clini Lung Cancer. 2017;18:105.CrossRef
6.
Zurück zum Zitat Verstegen NE, Oosterhuis JWA, Palma DA, Rodrigues G, Lagerwaard FJ, van der Elst A, et al. Stage I–II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann Oncol. 2013;24:1543–8.CrossRefPubMed Verstegen NE, Oosterhuis JWA, Palma DA, Rodrigues G, Lagerwaard FJ, van der Elst A, et al. Stage I–II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann Oncol. 2013;24:1543–8.CrossRefPubMed
7.
Zurück zum Zitat Robinson CG, DeWees TA, El NI, Creach KM, Olsen JR, Crabtree TD, et al. Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer. J Thorac Oncol. 2013;8:192–201.CrossRefPubMed Robinson CG, DeWees TA, El NI, Creach KM, Olsen JR, Crabtree TD, et al. Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer. J Thorac Oncol. 2013;8:192–201.CrossRefPubMed
8.
Zurück zum Zitat Kastelijn EA, El SS, Hofman FN, Van Putte BP, Monninkhof EM, Van Vulpen M, et al. Clinical outcomes in early-stage NSCLC treated with stereotactic body radiotherapy versus surgical resection. Anticancer Res. 2015;35:5607–14.PubMed Kastelijn EA, El SS, Hofman FN, Van Putte BP, Monninkhof EM, Van Vulpen M, et al. Clinical outcomes in early-stage NSCLC treated with stereotactic body radiotherapy versus surgical resection. Anticancer Res. 2015;35:5607–14.PubMed
9.
Zurück zum Zitat Van den Berg LL, Klinkenberg TJ, Groen HJ, Widder J. Patterns of recurrence and survival after surgery or stereotactic radiotherapy for early stage NSCLC. J Thorac Oncol. 2015;10:826–31.CrossRefPubMed Van den Berg LL, Klinkenberg TJ, Groen HJ, Widder J. Patterns of recurrence and survival after surgery or stereotactic radiotherapy for early stage NSCLC. J Thorac Oncol. 2015;10:826–31.CrossRefPubMed
10.
Zurück zum Zitat Zhang B, Zhu F, Ma X, Tian Y, Cao D, Luo S, et al. Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: a systematic review and meta-analysis. Radiother Oncol. 2014;112:250–5.CrossRefPubMed Zhang B, Zhu F, Ma X, Tian Y, Cao D, Luo S, et al. Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: a systematic review and meta-analysis. Radiother Oncol. 2014;112:250–5.CrossRefPubMed
11.
Zurück zum Zitat Puri V, Crabtree TD, Bell JM, Broderick SR, Morgensztern D, Colditz GA, et al. Treatment outcomes in stage I lung cancer: a comparison of surgery and stereotactic body radiation therapy. J Thorac Oncol. 2015;10:1776–84.CrossRefPubMedPubMedCentral Puri V, Crabtree TD, Bell JM, Broderick SR, Morgensztern D, Colditz GA, et al. Treatment outcomes in stage I lung cancer: a comparison of surgery and stereotactic body radiation therapy. J Thorac Oncol. 2015;10:1776–84.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Kohutek ZA, Wu AJ, Zhang Z, Foster A, Din SU, Yorke ED, et al. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer. Lung Cancer. 2015;89:115–20.CrossRefPubMed Kohutek ZA, Wu AJ, Zhang Z, Foster A, Din SU, Yorke ED, et al. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer. Lung Cancer. 2015;89:115–20.CrossRefPubMed
13.
Zurück zum Zitat Liu J, Dong M, Sun X, Li W, Xing L, Yu J. Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis. PLoS One. 2016;11:e146195. Liu J, Dong M, Sun X, Li W, Xing L, Yu J. Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis. PLoS One. 2016;11:e146195.
14.
Zurück zum Zitat Loganadane G, Martinetti F, Mercier O, Krhili S, Riet FG, Mbagui R, et al. Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a critical literature review of predictive factors of relapse. Cancer Treat Rev. 2016;50:240–6.CrossRefPubMed Loganadane G, Martinetti F, Mercier O, Krhili S, Riet FG, Mbagui R, et al. Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a critical literature review of predictive factors of relapse. Cancer Treat Rev. 2016;50:240–6.CrossRefPubMed
15.
Zurück zum Zitat He J, Huang Y, Shi S, Hu Y, Zeng Z. Comparison of effects between central and peripheral stage I lung cancer using image-guided stereotactic body radiotherapy via helical tomotherapy. Technol Cancer Res Treat. 2015;14:701–7.CrossRefPubMed He J, Huang Y, Shi S, Hu Y, Zeng Z. Comparison of effects between central and peripheral stage I lung cancer using image-guided stereotactic body radiotherapy via helical tomotherapy. Technol Cancer Res Treat. 2015;14:701–7.CrossRefPubMed
16.
Zurück zum Zitat Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence-what is it and what can it tell us? N Engl J Med. 2016;375:2293–7.CrossRefPubMed Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence-what is it and what can it tell us? N Engl J Med. 2016;375:2293–7.CrossRefPubMed
17.
Zurück zum Zitat Pan Y, Zheng D, Li Y, Cai X, Zheng Z, Jin Y, et al. Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer. J Thorac Dis. 2017;9:2579–86.CrossRefPubMedPubMedCentral Pan Y, Zheng D, Li Y, Cai X, Zheng Z, Jin Y, et al. Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer. J Thorac Dis. 2017;9:2579–86.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Shirvani SM, Jiang J, Chang JY, Welsh J, Likhacheva A, Buchholz TA, et al. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg. 2014;149:1244–53.CrossRefPubMedPubMedCentral Shirvani SM, Jiang J, Chang JY, Welsh J, Likhacheva A, Buchholz TA, et al. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg. 2014;149:1244–53.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Varlotto J, Fakiris A, Flickinger J, Medford-Davis L, Liss A, Shelkey J, et al. Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery. Cancer. 2013;119:2683–91.CrossRefPubMed Varlotto J, Fakiris A, Flickinger J, Medford-Davis L, Liss A, Shelkey J, et al. Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery. Cancer. 2013;119:2683–91.CrossRefPubMed
20.
Zurück zum Zitat Mokhles S, Verstegen N, Maat AP, Birim O, Bogers AJ, Mokhles MM, et al. Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis. Lung Cancer. 2015;87:283–9.CrossRefPubMed Mokhles S, Verstegen N, Maat AP, Birim O, Bogers AJ, Mokhles MM, et al. Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis. Lung Cancer. 2015;87:283–9.CrossRefPubMed
21.
Zurück zum Zitat Nair VJ, MacRae R, Sirisegaram A, Pantarotto JR. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status. Int J Radiat Oncol Biol Phys. 2014;88:312–8.CrossRefPubMed Nair VJ, MacRae R, Sirisegaram A, Pantarotto JR. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status. Int J Radiat Oncol Biol Phys. 2014;88:312–8.CrossRefPubMed
22.
Zurück zum Zitat Cerfolio RJ, Bryant AS. Survival of patients with true pathologic stage I non-small cell lung cancer. Ann Thorac Surg. 2009;88:917–23.CrossRefPubMed Cerfolio RJ, Bryant AS. Survival of patients with true pathologic stage I non-small cell lung cancer. Ann Thorac Surg. 2009;88:917–23.CrossRefPubMed
23.
Zurück zum Zitat Kim DH, Song BI, Hong CM, Jeong SY, Lee SW, Lee J, et al. Metabolic parameters using (18)F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:2051–7.CrossRefPubMed Kim DH, Song BI, Hong CM, Jeong SY, Lee SW, Lee J, et al. Metabolic parameters using (18)F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:2051–7.CrossRefPubMed
24.
Zurück zum Zitat Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8:740–801.CrossRefPubMed Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8:740–801.CrossRefPubMed
25.
Zurück zum Zitat Burdett, S, Pignon, JP, Tierney J, Tribodet H, Stewart L, & Le Pechoux C, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev. 2015;3: D11430. Burdett, S, Pignon, JP, Tierney J, Tribodet H, Stewart L, & Le Pechoux C, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev. 2015;3: D11430.
26.
Zurück zum Zitat Jumeau R, Bahig H, Filion E, Campeau MP, Lambert L, Roberge D, et al. Assessing the need for adjuvant chemotherapy after stereotactic body radiation therapy in early-stage non-small cell lung carcinoma. Cureus. 2016;8:e901.PubMedPubMedCentral Jumeau R, Bahig H, Filion E, Campeau MP, Lambert L, Roberge D, et al. Assessing the need for adjuvant chemotherapy after stereotactic body radiation therapy in early-stage non-small cell lung carcinoma. Cureus. 2016;8:e901.PubMedPubMedCentral
27.
Zurück zum Zitat Chen Y, Guo W, Lu Y, Zou B. Dose-individualized stereotactic body radiotherapy for T1-3N0 non-small cell lung cancer: long-term results and efficacy of adjuvant chemotherapy. Radiother Oncol. 2008;88:351–8.CrossRefPubMed Chen Y, Guo W, Lu Y, Zou B. Dose-individualized stereotactic body radiotherapy for T1-3N0 non-small cell lung cancer: long-term results and efficacy of adjuvant chemotherapy. Radiother Oncol. 2008;88:351–8.CrossRefPubMed
28.
Zurück zum Zitat Hamaji M, Chen F, Matsuo Y, Kawaguchi A, Morita S, Ueki N, et al. Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer. Ann Thorac Surg. 2015;99:1122–9.CrossRefPubMed Hamaji M, Chen F, Matsuo Y, Kawaguchi A, Morita S, Ueki N, et al. Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer. Ann Thorac Surg. 2015;99:1122–9.CrossRefPubMed
Metadaten
Titel
A SUVmax-based propensity matched analysis of stereotactic body radiotherapy versus surgery in stage I non-small cell lung cancer: unveiling the role of 18F-FDG PET/CT in clinical decision-making
Publikationsdatum
11.01.2018
Erschienen in
Clinical and Translational Oncology / Ausgabe 8/2018
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1819-7

Weitere Artikel der Ausgabe 8/2018

Clinical and Translational Oncology 8/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.